ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Caixin

In Depth: Questions persist over China's vaccine export deals

Sinovac and others already on the hook for 380m shots around the world

A Brazilian institute revealed that a Chinese vaccine from Sinovac had an efficacy threshold of 50%, but doubts were raised when the company said that vital data had been withheld.   © Reuters

China's experimental coronavirus vaccines are on the move. Global procurement data shows that three Chinese companies have inked deals to supply hundreds of millions of vials to the world in bilateral agreements with nations like Indonesia and Brazil.

The flashier mRNA vaccines of Pfizer-BioNTech and Moderna are more adaptable and have produced enviable results, but keeping them cold enough to prevent their delicate strands of genetic material from falling apart in transit is a major challenge.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more